The health tech and medtech investment landscape in the age of Covid-19
Fredrikson & Byron attorneys Ryan Johnson and Jeffrey Steinle share insights on how Covid-19 is continuing to transform the health tech and medtech landscape.
Fredrikson & Byron attorneys Ryan Johnson and Jeffrey Steinle share insights on how Covid-19 is continuing to transform the health tech and medtech landscape.
In a Spotlight Video interview, Fredrikson & Byron Shareholders and Co-chairs of the firm's life sciences group, Jeff Steinle and Ryan Johnson, talked about the deal-making environment in healthcare and how the Covid-19 pandemic has impacted it.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.